Pharma Investments, Ventures & Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures & Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Adenocarcinoma Therapy
Research from Washington University, Department of Surgery in adenocarcinoma therapy provides new insights
March 30th, 2008
Research findings, 'Enhanced susceptibility to chemical induction of ovarian tumors in mice with a germ line p53 mutation,' are discussed in a new report. According to a study from the United States, "Mice with a germ line p53 mutation (p53(Ala135Val/wt)) display increased susceptibility to lung, skin, and colon carcinogenesis. Here, we show that p53(Ala135Val/wt) mice developed ovarian tumors significantly more rapidly than their wild-type littermates after 7,12-dimethylbenz(a)anthracene (DMBA) treatment." "Approximately 50% of the ovarian tumors in p53(wt/wt) mice and 23% in p53(Ala135Val/wt) mice are adenocarcinomas and the remaining tumors were adenocarcinoma mixed...
Source: Pharma Investments, Ventures & Law Weekly (2008-03-30)
|
